

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

LOAN FACILITY WITH CHINA EVERBRIGHT BANK HONG KONG BRANCH- ANNOUNCEMENT PURSUANT TO RULE 13.18 OF THE LISTING RULES

The Company, as borrower, entered into the Facility Agreement with China Everbright Bank Hong Kong Branch for loan facility of up to HK\$200,000,000.

The Facility Agreement imposes, among other matters, specific performance obligations on the controlling shareholders of the Company.

This announcement is made pursuant to Rule 13.18 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”).

The board of directors (the “Board”) of The United Laboratories International Holdings Limited (the “Company”) announces that the Company, as borrower, entered into a facility agreement (the “Facility Agreement”) dated 8 December 2021 with China Everbright Bank Co., Ltd., Hong Kong Branch for uncommitted term loan facility of up to HK\$200,000,000 (or its equivalent amount in euro or USD). The term loan facility shall be available for drawdown within 3 months from the acceptance of the Facility Agreement. The term loan under the facility shall be repaid by instalment as 10%, 20%, 20% and 50% of all outstanding drawdowns as at the end of the term loan facility available period in the 18, 24, 30 and 36 months respectively from the date of first drawdown.

The Facility Agreement imposes, among other matters, Mr. Tsoi Hoi Shan, Ms. Choy Siu Chit, Ms. Ning Kwai Chun and their family trusts (i) individually or collectively do not cease to be the single largest shareholder of the Company; (ii) individually or collectively hold at least 40% of the entire issued capital of the Company; and (iii) do not cease to be the chairman of the Board and management control over the Company.

The Company will continue to comply with the disclosure obligations under Rule 13.21 of the Listing Rules for so long as circumstance giving rise to the above obligation continue to exist.

On behalf of the Board
The United Laboratories International Holdings Limited
Tsoi Hoi Shan
Chairman

Hong Kong, 15 December 2021

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Ms. Fu Xiao Nan as independent non-executive directors.